Pacira BioSciences, Inc. PCRX Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Pacira BioSciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Pacira BioSciences, Inc.'s financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Pacira BioSciences, Inc.'s financing cash flow?
- Pacira BioSciences, Inc. (PCRX) reported financing cash flow of -$59.4M in Q1 2026.
- How has Pacira BioSciences, Inc.'s financing cash flow changed year-over-year?
- Pacira BioSciences, Inc.'s financing cash flow decreased by 1883.9% year-over-year, from -$2.99M to -$59.4M.
- What is the long-term trend for Pacira BioSciences, Inc.'s financing cash flow?
- Over 3 years (2021 to 2025), Pacira BioSciences, Inc.'s financing cash flow has grown at a -1.0% compound annual growth rate (CAGR), from $380.69M to -$369.63M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.